Physician profile
James Case
NPI 1750866182
$35,977.53
in general payments reported to CMS, 2019-2025
24 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.52 · 2023: $193 · 2024: $380 · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Food and Beverage: $2,235 · Travel and Lodging: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,370.00 |
| Food and Beverage | $2,235.01 |
| Travel and Lodging | $1,311.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $33,681.00 | 2025 | |
| Amgen INC. | $673.48 | 2023-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.85 | 2022-2025 | Jardiance, Synjardy |
| Ascendis Pharma Endocrinology INC | $176.05 | 2025 | Yorvipath |
| Janssen Biotech, INC. | $130.01 | 2024 | Tremfya |
| Novo Nordisk INC | $129.32 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $108.96 | 2024-2025 | Mounjaro, Zepbound |
| Recordati_rare_diseases_inc. | $100.37 | 2022-2025 | Isturisa |
| Insulet Corporation | $92.65 | 2025 | Omnipod |
| Kyowa Kirin, INC. | $80.68 | 2023-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $77.93 | 2025 | Strensiq |
| Radius Health, INC. | $74.63 | 2023-2024 | Tymlos |
| Tandem Diabetes Care, INC. | $57.24 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $55.40 | 2024-2025 | |
| Medtronic, INC. | $55.07 | 2023-2025 | Minimed 780g |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $41.45 | 2025 | Dexcom G6 Transmitter |
| Intra-Sana Laboratories | $39.87 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Ani Pharmaceuticals, INC. | $32.68 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $29.71 | 2025 | Veozah |
| Amneal Pharmaceuticals LLC | $26.81 | 2025 | Unithroid |
| Abbott Laboratories | $21.77 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $21.61 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $21.56 | 2024 | Korlym |
| Ultragenyx Pharmaceutical INC. | $19.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.